en pharmacology pharmacology Original Article Original Article <span style="font-size:14px;"><span style="font-family:times new roman;"><span style="color:#0000FF;"><strong><em>Background</em></strong><em>:</em></span> Enteric-coated capsules are solid dosage forms which are designed to bypass the stomach and release the drug in the small intestine. This study was done to compare pharmacokinetics of ibuprofen tablet and ibuprofen as enteric-coated capsule using sodium alginate beads.<br> <span style="color:#0000FF;"><strong><em>Methods</em></strong><em>:</em></span> A crossover randomized study was performed on 12 healthy volunteers receiving a single dose of regular ibuprofen tablet (200 mg) and enteric-coated capsule (200 mg). The washout time between the periods was one month. Pharmacokinetic and pharmacodynamic blood samples were collected for 16 hours following treatment. High-performance liquid chromatography (HPLC) method used the following specifications: C18 column with 4.6 mm diameter & 25 mm length, the fluorescent detector of excitation and emission wavelengths were 224 and 290 nm, respectively.<br> <span style="color:#0000FF;"><strong><em>Results</em></strong><em>:</em></span> After a single oral dose of ibuprofen formulations, the median times to maximum concentration were 60 and 240 minutes in ibuprofen tablet (200 mg) and enteric-coated capsule, respectively. The maximum levels for the participants receiving ibuprofen tablet and enteric-coated capsule were 11.71&plusmn;1.3 and 10.32&plusmn;4.19 &micro;g/mL, respectively. The pharmacokinetic (PK) modeling data showed the area under curve (AUC) to be 61.51 hours & 86.62 hours for the group receiving the tablet and the capsule, respectively.<br> <span style="color:#0000FF;"><strong><em>Conclusion</em></strong><em>:</em></span> According to the results, in is concluded that enteric coating may delay the onset of ibuprofen effect and increases the duration of action. This formulation has advantages over the conventional drug delivery systems as it lengthens the dosing intervals and also increases patient compliance for chronic pain.</span></span> ibuprofen, pharmacokinetics, COX2-inhibitory effects 150 155 http://caspjim.com/browse.php?a_code=A-10-1133-1&slc_lang=en&sid=1 Yasaman Moghadamnia y.moghadamnia@gmail.com 100319475328460017346 100319475328460017346 No Alzahra University, Tehran, Iran Sohrab Kazemi kazemi.msm@gmail.com 100319475328460017347 100319475328460017347 No Cellular and Molecular biology research center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Boshra Rezaee BOSHRAREZAEE65@gmail.com 100319475328460017348 100319475328460017348 No Cellular and Molecular biology research center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Mehrdad Rafati-Rahimzadeh m.rafrahim@yahoo.com 100319475328460017349 100319475328460017349 No Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Soheil Ebrahimpour drsoheil.d@gmail.com 100319475328460017350 100319475328460017350 No Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Fahimeh Aghapour fahim.mfm@gmail.com 100319475328460017351 100319475328460017351 Yes Neuroscience Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran